Single-cell RNA-Seq reveals the potential risk of anti-mesothelin CAR T Cell therapy toxicity to different organs in humans

“On-target off-tumor” toxicity is a major challenge to the use of chimeric antigen receptor (CAR)-engineered T cells in the treatment of solid malignancies, because of the expression of target antigens in normal tissues. Mesothelin overexpression is associated with poor prognosis of multiple solid tumors, and would therefore appear to be a suitable antigen target. To understand the risk of toxicity to different organs on anti-mesothelin CAR T cell therapy, single-cell RNA sequencing (scRNA-seq) datasets derived from major human physiological systems were analyzed in this study, including the respiratory, cardiovascular, digestive, and urinary systems. According to scRNA-seq datasets, the organs were stratified into high or low risk based on the level of mesothelin expression. We report that the proportion of mesothelin-positive cells was 7.71%, 2.40% and 2.20% of myocardial cells, pulmonary cells and stomach cells, respectively, indicating that these organs could be at high risk of “on-target off-tumor” toxicity on anti-mesothelin CAR T cell therapy. By contrast, esophagus, ileum, liver, kidney and bladder exhibited low mesothelin expression (<1%). Therefore, these organs could be regarded as at low risk. Thus, the risk of toxicity to different organs and tissues in anti-mesothelin CAR T cell therapy may be predicted by these scRNA-seq data.

[1]  Qian Zhang,et al.  The antitumor capacity of mesothelin-CAR-T cells in targeting solid tumors in mice , 2021, Molecular therapy oncolytics.

[2]  S. Albelda,et al.  Mesothelin-targeted CAR-T cell therapy for solid tumors , 2020, Expert opinion on biological therapy.

[3]  Y. Hu,et al.  CAR T-cell therapy for triple-negative breast cancer: Where we are. , 2020, Cancer letters.

[4]  D. Torigian,et al.  Phase I Study of Lentiviral-Transduced Chimeric Antigen Receptor-Modified T Cells Recognizing Mesothelin in Advanced Solid Cancers. , 2019, Molecular therapy : the journal of the American Society of Gene Therapy.

[5]  Peng Li,et al.  Mesothelin as a biomarker for targeted therapy , 2019, Biomarker Research.

[6]  Suna Wang,et al.  Mesothelin is a target of chimeric antigen receptor T cells for treating gastric cancer , 2019, Journal of Hematology & Oncology.

[7]  E. Eyras,et al.  CD133-directed CAR T-cells for MLL leukemia: on-target, off-tumor myeloablative toxicity , 2019, Leukemia.

[8]  Lai Guan Ng,et al.  Dimensionality reduction for visualizing single-cell data using UMAP , 2018, Nature Biotechnology.

[9]  Liming Lu,et al.  Mesothelin-targeted second generation CAR-T cells inhibit growth of mesothelin-expressing tumors in vivo , 2018, Experimental and therapeutic medicine.

[10]  M. Shadman,et al.  Translating anti-CD19 CAR T-cell therapy into clinical practice for relapsed/refractory diffuse large B-cell lymphoma. , 2018, Blood.

[11]  D. Torigian,et al.  Activity of Mesothelin-Specific Chimeric Antigen Receptor T Cells Against Pancreatic Carcinoma Metastases in a Phase 1 Trial. , 2018, Gastroenterology.

[12]  C. Halberstadt What We Are. , 2017, JAMA.

[13]  K. Curran,et al.  Toxicity and management in CAR T-cell therapy , 2016, Molecular therapy oncolytics.

[14]  E. D. de Vries,et al.  Functional Genomic mRNA Profiling of a large cancer data base demonstrates mesothelin overexpression in a broad range of tumor types , 2015, Oncotarget.

[15]  Zhehai Wang,et al.  Chimeric antigen receptor for adoptive immunotherapy of cancer: latest research and future prospects , 2014, Molecular Cancer.

[16]  D. Torigian,et al.  Mesothelin-Specific Chimeric Antigen Receptor mRNA-Engineered T Cells Induce Antitumor Activity in Solid Malignancies , 2013, Cancer Immunology Research.

[17]  C. Sima,et al.  Mesothelin Overexpression Is a Marker of Tumor Aggressiveness and Is Associated with Reduced Recurrence-Free and Overall Survival in Early-Stage Lung Adenocarcinoma , 2013, Clinical Cancer Research.

[18]  K. Konstantopoulos,et al.  Mesothelin Binding to CA125/MUC16 Promotes Pancreatic Cancer Cell Motility and Invasion via MMP-7 Activation , 2013, Scientific Reports.

[19]  B. Levine,et al.  T Cells Expressing Chimeric Antigen Receptors Can Cause Anaphylaxis in Humans , 2013, Cancer Immunology Research.

[20]  S. Sleijfer,et al.  Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity. , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

[21]  C. Sima,et al.  Mesothelin Overexpression Promotes Mesothelioma Cell Invasion and MMP-9 Secretion in an Orthotopic Mouse Model and in Epithelioid Pleural Mesothelioma Patients , 2012, Clinical Cancer Research.

[22]  Q. Yao,et al.  Mesothelin confers pancreatic cancer cell resistance to TNF-α-induced apoptosis through Akt/PI3K/NF-κB activation and IL-6/Mcl-1 overexpression , 2011, Molecular Cancer.

[23]  S. Rosenberg,et al.  Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[24]  Shenmin Zhang,et al.  HSP70 INHIBITS APOPTOSIS IN PANCREATIC CANCER CELLS BY TWO INDEPENDENT MECHANISMS: ATTENUATING CYTOSOLIC CA2+ AND STABILIZING LYSOSOMES , 2007 .